Gitelman's syndrome (GS) is a rare, autosomal recessive, salt-losing tubulopathy caused by mutations in the SLC12A3 gene, which encodes the thiazide-sensitive NaCl cotransporter (NCC). Because 18 to 40% of suspected GS patients carry only one SLC12A3 mutant allele, large genomic rearrangements may account for unidentified mutations. Here, we directly sequenced genomic DNA from a large cohort of 448 unrelated patients suspected of having GS. We found 172 distinct mutations, of which 100 were unreported previously. In 315 patients (70%), we identified two mutations; in 81 patients (18%), we identified one; and in 52 patients (12%), we did not detect a mutation. In 88 patients, we performed a search for large rearrangements by multiplex ligationdependent probe amplification (MLPA) and found nine deletions and two duplications in 24 of the 51 heterozygous patients. A second technique confirmed each rearrangement. Based on the breakpoints of seven deletions, nonallelic homologous recombination by Alu sequences and nonhomologous end-joining probably favor these intragenic deletions. In summary, missense mutations account for approximately 59% of the mutations in Gitelman's syndrome, and there is a predisposition to large rearrangements (6% of our cases) caused by the presence of repeated sequences within the SLC12A3 gene.
Gitelman's syndrome (GS, MIM 263800) is a rare salt-losing tubulopathy 1 characterized by hypokalemic metabolic alkalosis, hypomagnesaemia, and hypocalciuria. Loss of function mutations in the SLC12A3 gene encoding for the thiazide-sensitive NaCl cotransporter (NCC) are responsible for most of the cases. 2, 3 GS is inherited as an autosomal recessive trait, and homozygous and combined heterozygous mutations are expected. 1 However, between 18 and 40% of patients with clinical GS are usually found to carry only one mutant allele after SLC12A3 screening. 4 -6 These incomplete genetic results raise the possibility of an excess of clinically suspected cases, genetic heterogeneity, or a failure in the mutation detection process. These issues have already been extensively discussed. 7, 8 However, genetic heterogeneity also exists, and a minority of patients with the GS phenotype harbor mutations at the CL-CNKB gene. 9, 10 An important cause of apparently negative genetic testing could be large genomic rearrangements that are missed by direct sequencing and that usually account for 5 to 15% of the molecular defects responsible for autosomal recessive diseases. 11, 12 Several techniques exist for detecting these large deletions or insertions, such as the multiplex ligation-dependent probe amplification (MLPA) assay 11, 13 or the quantitative multiplex PCR of short fluorescent fragments (QMPSF), 14 previously used in our laboratory. 15 However, to date, a systematic screening for large genomic rearrangements at the SLC12A3 gene in GS is lacking, and only 1 16 of the 143 reported mutations in the Human Gene Mutation Database (http://www.hgmd.cf.ac.uk/ac/index.php) is a large genomic rearrangement.
Here we report the molecular analysis of the SLC12A3 gene in a large cohort of 448 patients in whom GS was suspected. Direct sequencing showed homozygosity and combined heterozygosity in 70% of patients and only one mutated allele in 18% of patients, and a search for large genomic rearrangements was performed in 88 GS patients (51 heterozygous for point mutations 26 without mutation and 11 patients with homozygous mutations without consanguinity history). We show that large rearrangements may account for Ն6% of all mutations detected at the SLC12A3 gene in GS patients and therefore could improve the sensitivity of genetic testing to Ͼ80%.
RESULTS

Results of the First Screen by Direct Sequencing Analysis
Of 448 index cases, two affected alleles were identified in 315 patients (70%): 79 of them were homozygous (25%) and 236 were compound heterozygous (74.9%). Only one mutant allele was detected in 81 patients (18%), and the wild-type genotype was detected in 52 patients (11.6%). The list of point mutations found is given in Supplementary Table 1: 172 different mutations were detected, spread throughout the gene. These included 64% missense, 14% frameshift, and 2% in-frame small deletions or insertions and 14% splice and 6% nonsense mutations. Figure 1 shows the distribution of the 711 mutated alleles along the 26 exons of the SLC12A3 gene. There were seven recurrent mutations, recurrence being defined arbitrarly by an allele frequency Ͼ2%, and included five missense amino acid changes found in 217 alleles (199 patients) and two splice mutations detected in 78 alleles (57 patients). They were mainly found in heterozygous compound subjects, except for c.1180 ϩ 1GϾT, which is highly prevalent in the Gypsy population. 17 In the entire set of 172 point mutations, 100 have not been described before (53 missense, 19 frameshift, 16 splice, 6 nonsense, and 6 in-frame mutations; Supplementary Table 1 , A-C). Supplementary Table 2 sums up the novel missense mutations and their in silico predictions.
Screening for Genomic Rearrangements in Simple Heterozygotes
We decided to screen for large rearrangements at the SLC12A3 gene in patients with only one mutation detected by direct sequencing. Only 51 of the 81 samples were of sufficient DNA quality to be screened by MLPA or QMPSF. Rearrangements were found in 24 of them (47%, Table 1 ); single exon deletions were observed in 13 samples (E9del, n ϭ 1; E14del, n ϭ 2; E18del, n ϭ 1; E26del, n ϭ 9); deletions of two or more exons were detected in 9 samples (E1_E7del, n ϭ 2; E2_E3del, n ϭ 2; E4_E5del, n ϭ 3; E19_E23del, n ϭ 1; E24_E25del, n ϭ 1); and duplications were detected in 2 samples (E1_E3dup and E1_E4dup). Two examples of these rearrangements are shown in Figure 2A .
As a second screening, we performed QMPSF analysis targeting the exon 6 of the SLC12A3 gene, not included in MLPA kit. This screening allowed the detection of E6del in only the three patients harboring the E4_E5del, thus extending the deletion to exon 6 (E4_E6del). QMPSF was also used to confirm E26del detected in nine patients, E19_E23del, and E1_E3dup ( Figure 2B ).
Clinical and biologic features of patients harboring one heterozygous rearrangement are shown in Table 2 . All had a profound hypokalemia accompanied with metabolic alkalosis and usually hypomagnesaemia.
The updated spectrum of mutations detected in our cohort of GS patients, including genomic rearrangements, is shown in Figure 3 . Whereas missense mutations were the majority (59%), small insertions or deletions detected by direct sequencing represent 14% and large rearrangements detected by MLPA and QMPSF accounted for 6% of the entire set of mutations.
Further Genetic Screening in Subjects with No
SLC12A3 Mutation
Because the phenotype caused by CLCNKB mutations may vary from the various types of Bartter syndrome to GS, we first analyzed the CLCNKB gene (sequencing and MLPA or QMPSF) in 49 of the 52 patients who tested negative for the SLC12A3 gene. Mutations were detected in 14 patients; Supplementary Table 4 , A and B, summarizes the mutations detected and clinical data of these patients. We performed a search for genomic rearrangements in SLC12A3 gene by MLPA and QMPSF in 26 of those 38 remaining patients for whom the DNA quality was sufficient. No abnormality was detected, suggesting either another mutation at the SLC12A3 gene that was not detected by our screening or further genetic heterogeneity. Patients without mutations had similar features to the SLC12A3 mutated patients (Supplementary Table 3 ).
Further Genetic Screening in Homozygous Subjects without Notion of Consanguinity
In a subset of 28 patients belonging to the group of homozygous patients, the SNPs detected along the gene were homozygous, despite the absence of consanguinity. To exclude one heterozygous deletion, we were able to perform MLPA in 11 of them. Neither deletions nor duplications were detected in this group.
Characterization of the Deletion Breakpoints
Long-range PCR completed by direct sequencing of the abnormal allele was first performed in nine patients (Supplementary Figure  1) . Six different deletions (from 1.1 to 10.7 kb size) were found ( Figure 4A ): E2_E3del in two patients (c.282 ϩ 667_c.506 -205del and c.283-273_c.506 -213del), the same E4_E6del We also paid particular attention to a patient and his family with a large deletion containing the 5Ј part of the gene up to exon 7 ( Figure 5A ). First, single nucleotide polymorphism (SNP) segregation analysis was performed by genotyping 16 SNPs at the SLC12A3 locus. The proband was homozygous for 14 of the16 SNPs, whereas his mother was heterozygous for 4 of the 7 SNPs lying in the intergenic region proximal to the SLC12A3 gene and for 7 of 9 SNPs in the NUP93 gene ( Figure  5B1 ). Thus, the deletion mapped in an 89.9-kb region between rs2043635 (intron 5 of NUP93 gene; 56,818,987 Mb [hg19]) and rs11640954 (intron 8 SLC12A3 gene; 56,908,884 Mb [hg19]). To define this more precisely, we performed comparative genomic hybridization microarray analysis that allowed limiting the deletion size to 13,090 bp ( Figure 5B2 ). On the centromeric side (q-arm), the closest probe that tested positive was mapped at position 56,899,150 Mb within the 5ЈUTR of SLC12A3. On the telomeric side, the closest probe that tested positive was located in exon 9 of SLC12A3 at position 56,912,240 Mb.
High Number of Low Copy Repeats Sequences Favor Most Intragenic Deletions
Sequence alignment using RepeatMasker allowed identification of the presence of 41 Alu and 11 LINEs sequences within the SLC12A3 gene. Interestingly, the breakpoints of all of the genomic rearrangements identified in our patients contained low copy repeats (LCRs; Figure 4 , A and B). For example, the 3342-and 2720-bp E2_E3del probably originated from the For two other deletions, the 1.1-kb E14del and the larger 10.7-kb E24_25del, the breakpoints were within nonhomologous LCRs: an AluY and a MER115 repeat in introns 13 and 14 and L2a_LINE and L2b_Line repeats in introns 23 and 25, respectively ( Figure 4A ). The sequence alignments at the breakpoint junctions for these two deletions showed six nucleotides with microhomology for the 10711-bp deletion and three nucleotides with microhomology and GAG rearrangement-promoting elements for the 1183-bp deletion ( Figure 4C , deletions 2 and 4). These data strongly suggest nonhomologous end-joining as the causal mechanism for these deletions, facilitated by the presence of rearrangement-promoting elements inside the LCRs.
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www.jasn.org crossing over between two different AluSx repeats in intron 1 (312 and 237 bp) and the same AluSx repeat in intron 3 (256 bp). Similarly, the breakpoints for the 1508-bp deletion, which includes exons 4 to 6, were inside a sequence shared by the 256-bp AluSx repeat in intron 3
A Particular Rearrangement Was Observed for the Recurrent E26del
Taking into account the data obtained in the characterized deletions, we searched whether LCRs could also explain the recurrent E26del. Indeed, four AluSx and two AluJb are dispersed in intron 25 and one AluSx ϳ500 bp after the stop codon. Long-range PCR amplification performed with a forward primer in exon 25 and a reverse primer distal to AluSx in the 3Ј breakpoint resulted in the amplification of two bands in the nine patients with E26del detected by MLPA (Supplementary Figure 2) . Direct sequencing of the short product showed the same complex rearrangement in the nine unrelated patients: a 2412-bp deletion with a 25-bp insertion (c.2952-1593_*677delins25). The 5Ј breakpoint is 50 bp after an ALuJb repeat in intron 25, and the 3Ј breakpoint is inside an AluSx repeat in the 3ЈUTR region ( Figure 4A and 4C) .
DISCUSSION
Based on a complete molecular investigation of the SLC12A3 gene on the largest cohort reported thus far, we showed the value of combining several techniques to finally achieve an 91% mutation detection rate in GS. Next to the identification of missense mutations (59% of the cases) and small insertions or deletions (14%) by direct sequencing, we used MLPA and QMPSF, which allowed the detection of large rearrangements in 24 of 51 GS patients (47%) known to be heterozygous for a point mutation. This suggests that almost one half of the patients suspected to have GS with only one mutated allele detected by direct sequencing (18% of our series and of the smaller series described by Ji et al. 6 ) have a large genomic rearrangement on the other allele.
To date, Ͼ180 mutations in SLC12A3 have been reported, about 70% of which being missense mutations. In this study, direct sequencing allowed the detection of 110 different missense mutations in 290 subjects (64% of the mutations found), 51 of them being novel. Supplementary Table 2 sums up in silico predictions for these changes. None of these amino acid changes are known SNPs, and they were not detected in 200 control chromosomes. Furthermore, they were not detected either in 220 control chromosomes in another European study, 5 and only one (p.Gly779Glu) was detected (allelic frequency of 0.02%) in 1985 unrelated subjects from the Framingham cohort. 6 This missense change was predicted as functional and was associated with lower BP. Taken together, the novel 51 missense mutations described in this paper are rare variants very likely to be pathogenic.
Five previously described missense mutations were particularly frequent in our unrelated patients (Figure 1 ), raising the possibility of neutral polymorphisms. Two of them, p.Gly741Arg and p.Cys994Tyr detected in 36 and 38 patients, respectively, led to a total or partial loss of function when expressed in vitro into Xenopus laevis oocytes. 18, 19 Mutations p.Leu859Pro and p.Arg861Cys have not been expressed in vitro; however, three in silico methods predicted these amino acid changes to be pathogenic. Thus, there are strong arguments for p.Gly741Arg, p.Cys994Tyr, p.Leu859Pro, and p.Arg861Cys being hotspot mutations. In contrast, the previously reported p.Ala313Val mutation was predicted in silico as nondeleterious. This variant was detected in 19 GS patients: it was associated with a second pathogenic mutation in 18 patients and was homozygous in 1 patient, suggesting that it is deleterious.
All mutations described in this study, including large rearrangements and the 100 novel point mutations, will be available online at the European Network for the Study of Orphan Nephropathies website (http://www.eunefron.org/). One of our major findings was the detection of large rearrangements in GS patients, representing about one half of the heterozygous patients tested. The breakpoints of these largescale mutations were found to correspond to a high frequency of repetitive sequences within the SLC12A3 gene. More than a million of Alu sequences are dispersed throughout the genome, and regions with high Alu repeat content are prone to nonallelic homologous recombination, which may cause inherited diseases. 20 The SLC12A3 gene contains 41 Alus and 11 LINEs dispersed in intronic regions corresponding to 22.5 and 6% of the gene sequence, respectively. Four of seven deletions were the consequence of Alu-mediated recombination: AluSx sequences involved in E2_E3del and in E4_E6del in two and three patients, respectively, and the AluSx and AluY sequences involved in E18del share Ͼ80% identity. The breakpoints of two other deletions were located in nonhomologous LCRs: AluY and MER115 for E14del and L2a and L2b_LINE for E24_E25del. However, we observed nucleotide microhomology and, in one case, the presence of the recombinant-promoting element GAG at breakpoint junctions. These data correspond to the characteristics observed in the nonhomologous end-joining mechanism. 21 This mechanism, used by eukaryotic cells to repair double-strand DNA breaks, could be stimulated by genomic architecture (i.e., LCRs and sequence motifs).
The breakpoints analysis of the recurrent E26del detected in probands of nine unrelated families showed the presence of a complex indel mutation (2412-bp deletion and 25-bp insertion). The 5Ј breakpoint was in close proximity to AluJb and the 3Ј breakpoint was inside an AluSx. Repetitive motifs were detected in the insertion and in the 3Ј breakpoint ( Figure 4C , deletion 7). Similar indels have been described in the NF1 and CFTR genes. 22, 23 A multistep mechanism facilitated by the presence of LCRs is likely to favor them, as has been suggested for other complex rearrangements. 24 The deletions and duplications detected have not been described as copy number variants in healthy controls (Database of Genomic Variants at http://projects.tcag.ca/variation/, Copy number variation project at the Children's Hospital of Philadelphia at http://cnv.chop.edu, and 1000 Genomes at http://browser. 1000genomes.org/index.html).
Of note, large-scale mutations were not associated with a more severe phenotype when clinical and biochemical data from patients harboring a heterozygous deletion were compared with those from subjects homozygous or compound heterozygous for two missense mutations.
This mmol/L). Also, the heterozygous E1_E7del was detected in two patients: one with a relatively severe phenotype and the other one with a mild phenotype. This deletion was identified previously in one homozygous and one heterozygous member of an Amish kindred, 16 who were not mentioned as having a particularly severe phenotype compared with the 48 other GS patients. Thus, a null allele does not seem to be more detrimental than a punctual loss of function mutation, although the nature and position of SLC12A3 mutations have been thought to influence the severity of GS. 5 Concerning the group of patients without mutations, most of them have a GS-like phenotype. Only three of them had an early presentation (BT100, B001, and B059 in Supplementary Table 2) . In these patients, another cause of severe hypokalemic metabolic alkalosis such as congenital chloride diarrhea could be considered. Ch. 16 rs7202364  rs2043635  rs12444217  rs1529929  rs7199480  rs4784730  rs1347591  rs12445993  rs12443821  rs12932041  rs4784732  rs1436424  rs12920659  rs12599065  rs12921781  rs3829502  rs11640954 Nevertheless, in these patients, there was no history of polyhydramnios, premature birth, or diarrhea. Furthermore, urinary electrolytes at diagnosis or on follow-up (5 to 10 years) showed sodium, potassium, and chloride wasting.
In conclusion, this molecular analysis of a large cohort of 448 GS patients, including the first search for large-scale mutations, showed that, despite the high efficiency of direct genomic sequencing in detecting the vast majority of the SLC12A3 mutations found in this disorder, a complementary technique is necessary to achieve a high mutation detection rate, especially for those patients in whom only one mutation had been detected. We confirmed that MLPA is an efficient technique for analyzing large genomic rearrangements, which account for Ն6% of mutations detected in our patients with GS. Moreover, we showed that nonallelic homologous recombination by Alu sequences and nonhomologous end-joining are most likely to be responsible for intragenic deletions. Finally, we detected CLCNKB mutations in 3% and excluded mutations and large rearrangements of the SLC12A3 gene in 8% (n ϭ 36) of our GS patients, which questions the clinical diagnosis of GS and raises the possibility of genetic heterogeneity in this inherited tubulopathy.
CONCISE METHODS
Patients
Between January 2001 and August 2009, samples from 448 probands (219 males and 229 females) with a clinical diagnosis of GS were received at the Genetics Department at Hopital Européen Georges Pompidou, Paris. Most samples were sent from nephrology and endocrinology services thanks to the French Network for Tubulopathies and the European Network for the Study of Orphan Nephropathies (http://www.eunefron.org/). A few samples (n ϭ 6) were also received from other countries (Austria, Canada, Luxemburg, and Portugal). Appropriate informed consent was obtained from all patients and their families. They were selected according to the classical criteria for GS: renal hypokalemia, metabolic alkalosis, hypomagnesaemia, hypocalciuria, and secondary hyperreninism and hyperaldosteronism. Nevertheless, because plasma renin and aldosterone were not measured in all cases at diagnosis and because the absence of hypomagnesaemia or hypocalciuria has been described in some genetically confirmed cases, 25, 26 we did not systematically require all of the criteria to be met before performing the genetic testing.
Detection of Point Mutations
Total DNA was extracted from blood peripheral leukocytes by standard procedures. Mutation analysis was performed by PCR amplification and direct sequencing of exons and flanking intronic sequences of the SLC12A3 gene, mainly as described previously 4 (primers available upon request), on an ABI Prism 3730XL DNA Analyzer Sequencer (Perkin Elmer Applied Biosystems, Foster City, CA).
Two amino acid changes initially described as mutations and then as SNPs were considered as SNPs in this study: p.Arg913Gln (rs11643718) and p.Ala728Thr (rs61730207). In contrast, we considered the amino acid changes p.Arg209Trp (SNP rs28936388), p.Gly264Ala (SNP rs1529927), and p.Arg928Cys (SNP rs12708965) as loss of function mutations. Indeed, in vitro expression of p.Arg209Trp and p.Gly264Ala has been shown to produce a significant reduction in NCC activity, 18, 27 and the p.Arg928Cys change is predicted in silico to be deleterious and is also considered diseasecausing. 6 Eight novel missense changes detected in this study (p.Ala13Pro, p.Arg83Gln p.Val404Ile, p.Thr428Pro, p.Ser546Gly, pSer833Leu, p.Glu915Ala, and p.Gln1021Lys) were predicted in silico as nondeleterious (Supplementary Table 2 ) and were characterized as variants of unknown significance. The p.Ala322Val was also predicted as nondeleterious, but this change implicates the first nucleotide of exon 8 and may be considered as a splice mutation. Indeed, ESEfinder (at http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder) predicts a loss of two enhancer motifs (SRp55 and SF2/ASF).
MLPA Analysis
We used a commercially available kit, the SALSA MLPA P136 SLC12A3 Kit (MRC Holland, Amsterdam, The Netherlands) to detect large deletions or duplications in the SLC12A3 gene. The P136 kit contains 38 probes: 25 probes for SLC12A3 (one for each exon except exon 6) and 13 reference probes. The detailed procedure is described in Supplementary Materials.
QMPSF
We adapted the QMPSF method 28 to detect large deletions or duplications at the SLC12A3 gene. Details of the procedure are given in Supplementary Materials and the corresponding primers in Supplementary Table 3 . This method was used to amplify exon 6 of the SLC12A3 gene, which is not included in the MLPA SLC12A3 kit. It was also used to confirm deletions or duplications found by MLPA, especially when it was difficult to estimate the 3Ј (exon 26) or 5Ј breakpoints limits (duplication of exons 1 to 3 and 1 to 4) or if no amplification was obtained by long-range PCR (deletion of exons 19 to 23).
Mapping the Deletion Breakpoints by long-range PCR
Long-range PCR and sequencing analysis were performed in 10 patients to confirm the MLPA results and to determine the deletion breakpoints. Gene-specific primers located in proximal and distal nondeleted exons were designed for each type of deletion (Supplementary Table 4 ). Detailed of the procedure can be found in Supplementary Materials.
Characterization of Patient BT213's Deletion Table 5 ). Two SNPs located in intron 8 (rs11640954 and rs34136389) were also genotyped in the patient and his mother to confirm heterozygosity in this region.
2. Further analysis by comparative genomic hybridization: to analyze the deletion breakpoints, we performed a whole genome array compara-tive genomic hybridization analysis using an Agilent 244k oligonucleotide array (Agilent, Santa Clara, CA). The complete procedure is given in Supplementary Materials.
Bioinformatic Analysis of Mutations
Mutation interpretation and amino acid conservation in orthologs were assessed using Alamut V. 
